This molecular architecture provides a unified mechanistic explanation for the dual phenotype of TRIM hyperinflammation (e.g., TRALI) and immunosuppression (e.g., postoperative infections, tumor recurrence) in transfused patients. This evidence concerns the gene TRAT1 and neoplasm.